Clin Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leichter, S. B.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Leichter, S. B.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Clinical Diabetes 23:6-8, 2005
© American Diabetes Association ®, Inc., 2005


The Business of Diabetes

The Coming Crisis in Continuing Education in Diabetes: Resolvable Issues and Novel Solutions

Steven B. Leichter, MD, FACP, FACE

The first 300 words of the full text of this article appear below.


    Introduction
 
In a previous article,1 a broad theoretical concept was presented that suggested that physician participation in continuing medical education (CME) programs was diminishing and would continue to diminish. The reasons suggested for this were:

  1. Growing dependence on pharmaceutical companies for financial support of CME programs
  2. Increasing pressure for regulatory oversight of educational programs sponsored by pharmaceutical companies
  3. Increasing and negative imposition of "ethical standards" for physician behavior by pharmaceutical companies in CME interactions
  4. Despite regulatory oversight, growing pharmaceutical company control of the development and marketing of physician "experts" for CME, whether promotional or accredited
  5. With increased regulatory oversight, a decline in the degree of creativity and level of sophistication of such programs, converting many CME or promotional programs into "infomercials."

According to unofficial but authoritative sources in various pharmaceutical companies, these influences have resulted in a substantial decline in physician participation in CME programs. Despite these trends, there is no evidence that the current directions will be altered in the near future. Altering these characteristics would be very desirable in diabetes care.


    The Need for CME in Diabetes Care
 
Multiple studies have confirmed that the prevalent level of care for diabetic patients is demonstrably deviant from recommended guidelines and procedures.2-7 This has been documented in various care settings, including primary care, family practice, and large urban managed care organizations.

Despite vigorous efforts on the part of the American Diabetes Association (ADA) and other organizations to remedy these deviations, there is no compelling evidence that such efforts have substantially improved these gaps in care. A study on the impact of the Canadian Diabetes Association's clinical practice guidelines for postpartum screening of pregnant women with gestational diabetes for type 2 diabetes demonstrated that the guidelines had no significant effect.8 The failure of such educational efforts in diabetes reflects a widespread failure of CME efforts to improve clinical practice.9 . . . [Full Text of this Article]

Barrier 1: Application of "Ethical Guidelines" on Postgraduate Physician Education
Barrier 2: Increasing Restrictions on Accredited Programs

    Summary
 

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.